Aspira Women's Health Inc. Stock price

Equities

AWH

US04537Y2081

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
3.1 USD -9.62% Intraday chart for Aspira Women's Health Inc. -10.79% -24.02%
Sales 2023 * 9.58M Sales 2024 * 14.2M Capitalization 40.16M
Net income 2023 * -17M Net income 2024 * -16M EV / Sales 2023 * 4.19 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 2.83 x
P/E ratio 2023 *
-1.79 x
P/E ratio 2024 *
-2.46 x
Employees 85
Yield 2023 *
-
Yield 2024 *
-
Free-Float 57.54%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Aspira Women's Health Inc., Q4 2023 Earnings Call, Mar 28, 2024
Earnings Flash (AWH) ASPIRA WOMEN'S HEALTH Posts Q4 Revenue $2.1M MT
Aspira Women's Health Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Aspira Women's Health Inc. Announces Executive Changes CI
Aspira Women's Health Inc. Announces OvaSuite(SM) Distribution Agreement in the Philippines CI
Aspira Women's Health Inc. announced that it expects to receive $5.5 million in funding CI
Transcript : Aspira Women's Health Inc. - Special Call
Aspira Women's Health Inc. Announces Resignation of Veronica G.H. Jordan from the Board of Directors CI
Aspira Women's Health Provides Development Update on its Portfolio of Noninvasive Tests for Endometriosis CI
Aspira Women's Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services CI
Transcript : Aspira Women's Health Inc., Q3 2023 Earnings Call, Nov 13, 2023
Earnings Flash (AWH) ASPIRA WOMEN'S HEALTH Posts Q3 Revenue $2.2M, vs. Street Est of $2.9M MT
Aspira Women's Health Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Aspira Women's Health Sees Poster on its MiRNA-Based Ovarian Cancer Test Presented at the AACR Special Conference in Cancer Research CI
Aspira Women's Health Establishes A New Clinical Advisory Board CI
More news

Latest transcript on Aspira Women's Health Inc.

1 day-9.62%
1 week-10.79%
Current month-21.52%
1 month-23.46%
3 months-17.77%
6 months-42.91%
Current year-24.02%
More quotes
1 week
2.91
Extreme 2.9101
3.75
1 month
2.91
Extreme 2.9101
4.29
Current year
2.91
Extreme 2.9101
5.65
1 year
2.31
Extreme 2.3087
6.75
3 years
2.31
Extreme 2.3087
109.50
5 years
2.31
Extreme 2.3087
158.10
10 years
2.31
Extreme 2.3087
158.10
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 21-02-21
Director of Finance/CFO 55 23-06-14
Compliance Officer - -
Members of the board TitleAgeSince
Director/Board Member 68 23-05-08
Director/Board Member 60 23-05-08
Chairman - 23-05-08
More insiders
Date Price Change Volume
24-03-28 3.1 -9.62% 38,687
24-03-27 3.43 -2.00% 24,759
24-03-26 3.5 -1.69% 21,458
24-03-25 3.56 -2.47% 19,172
24-03-22 3.65 +1.11% 14,010

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Aspira Women's Health Inc. is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. Its products include Ova1, Overa, Ova1Plus and OvaWatch. Ova1 is a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy. Overa is a biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity. Ova1Plus is a reflex offering, which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results. OvaWatch is a lab developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass. The Company's products are distributed through its own national sales force, through its decentralized testing platform.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
3.1 USD
Average target price
5.6 USD
Spread / Average Target
+80.65%
Consensus
  1. Stock
  2. Equities
  3. Stock Aspira Women's Health Inc. - Nasdaq